Dezoxide Suppresses Sufentanil-induced Cough

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

176 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-09-12

Study Completion Date

2023-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Dizocine (0.03 mg/kg) or saline followed by sufentanil 0.4ug/kg was administered, and induction was completed with 3 min of observation. Heart rate and mean arterial pressure (MAP) were recorded before induction of anesthesia, before and 1 min after intubation, and side effects during induction, such as vomiting, hypoxemia (SpO2 \<90%), or other expected effects. The number of coughs was recorded in both groups, and the severity of cough was defined as follows: mild, 1-2 coughs; moderate, 3-4 coughs; severe, 5 or more coughs.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy of Dexmedetomidine for Cough Suppression in Patients Undergoing Thyroid Surgery

NCT03312413

Anesthesia Complication

UNKNOWN PHASE4

Effect of Dexmedetomidine in Preventing Cough and Postoperative Pain After Laryngeal Surgery for Cancer

NCT03918889

Laryngectomy; Status

UNKNOWN NA

Effects of Different Doses of Dexmedetomidine on Fentanyl-induced Cough

NCT03126422

Fentanyl-induced Cough

UNKNOWN PHASE1

Effect of Dezocine Combined With Sufentanil on the Quality of Postoperative Recovery and Analgesic Effect in Patients Undergoing Thoracic Surgery

NCT06439368

Rehabilitation Postoperative Pain

RECRUITING PHASE4

Antitussive Effect of Single-dose Dexmedetomidine With Low-dose Remifentanil Infusion

NCT02208505

Thyroidectomy

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sufentanil-induced Cough

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

control

Group Type NO_INTERVENTION

No interventions assigned to this group

Dezocine

intravenous dezocine (0.03mg/kg diluted to 5 ml)

Group Type EXPERIMENTAL

Intravenous dizocine

Intervention Type DRUG

Intravenous dizocine (0.03mg/kg diluted to 5 ml)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Intravenous dizocine

Intravenous dizocine (0.03mg/kg diluted to 5 ml)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients admitted for elective valve surgery, artificial vessel replacement or coronary artery bypass graft surgery; Age 18\~80 years old; Sex is not limited; ASA class II\~III; NYHA Class II-III; Patients or their family members have signed the clinical trial informed consent form

Exclusion Criteria

* Upper respiratory tract infection within the last two weeks; Long history of smoking; chronic obstructive pulmonary disease; Highly reactive airway diseases such as bronchitis and asthma; Presence of high cranial pressure, high eye pressure, pulmonary alveolus; Malignant tumor, hematological disease, severe liver and kidney dysfunction, recent serious infection, etc.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No